AI
Written with AI assistanceā¢February 20, 2026ā¢
AI
Generated IllustrationAn investigation by NGO OxySuisse has uncovered numerous collaborations between the tobacco industry, particularly Philip Morris International, and at least 16 Swiss academic institutions, raising concerns about research independence.
"For decades, the tobacco industry has used scientific collaboration to gain legitimacy, minimise the risks of its products, and influence health policies, often in a covert manner."
"The actual number may be higher due to non-disclosure and confidentiality clauses."
Switzerland is plummeting in global ethical standings, now ranking a shameful 99th out of 100 countries in the 2025 Global Tobacco Industry Interference Index. This alarming statistic is not merely a number; it is a damning indictment of the nation's vulnerability to corporate manipulation. A bombshell investigation by the NGO OxySuisse has shattered the illusion of academic neutrality, exposing a staggering 29 collaborations between the tobacco industry and Swiss higher education institutions since 2019.
The report paints a disturbing picture of infiltration across the entire academic spectrum. From prestigious universities and federal institutes of technology to university hospitals, at least 16 institutions have opened their doors to tobacco money. These are not passive donations but active entanglements involving joint research, workshops, and even doctoral theses. While Switzerland prides itself on scientific excellence, this investigation suggests that the very foundation of this researchāindependenceāis being eroded by an industry desperate to whitewash its reputation. The sheer scale of these links indicates that this is not an anomaly, but a systemic failure to protect public health interests from private profit.
One corporate giant looms larger than any other over Swiss lecture halls: Philip Morris International (PMI). In a revelation that underscores the company's aggressive strategy, OxySuisse identified that PMI is the driving force behind 23 of the 29 uncovered collaborations. This is not a diverse array of corporate partners; it is a near-monopoly on influence by a single tobacco titan.
The nature of these partnerships is deeply strategic. By embedding itself into the fabric of Swiss academia through teaching assignments and joint publications, PMI effectively purchases scientific legitimacy. This mirrors the tactics exposed by the University of Bath and Le Monde, which describe a "systematic and planned strategy" rather than isolated incidents of corporate charity. In Switzerland, this strategy has historical roots, recalling the infamous Rylander scandal where Philip Morris financed research on passive smoking at the University of Geneva. Today, the tactics have evolved, but the goal remains the same: to influence health policy and minimize perceived product risks from within the ivory tower.
The extent of the tobacco industry's reach may be far deeper than currently known, as a culture of secrecy pervades these academic agreements. Most alarmingly, OxySuisse warns that the confirmed 29 collaborations are likely just the tip of the iceberg, obscured by non-disclosure agreements and confidentiality clauses. When the NGO attempted to shine a light on these dealings, they were met with stonewalling.
Four major institutions flatly refused to provide information or publish contracts, forcing OxySuisse to resort to legal proceedings to extract the truth. In a victory for public accountability, every legal challenge decided so far has gone in favor of the NGO or been supported by cantonal transparency offices. This resistance to disclosure raises a critical question: If these collaborations are purely scientific and ethical, why are institutions fighting so hard to keep them hidden? The refusal to cooperate suggests a profound awareness that these partnerships may not withstand public scrutiny.
As the credibility of Swiss research hangs in the balance, the time for passive observation is over. OxySuisse is demanding immediate, binding national ethics rules to replace the current patchwork of vague guidelines that have allowed this infiltration to fester. The NGO asserts that without mandatory transparency, the scientific integrity of the nation remains under threat.
To combat the silence from above, OxySuisse has activated a secure "whistleblower" channel. This tool empowers researchers and university staff to bypass administrative gatekeepers and confidentially report violations of scientific integrity. This move shifts the power dynamic, allowing those within the system to expose the rot without fear of retaliation. With the Swiss tobacco ad ban set to protect minors starting in 2027, the country is slowly waking up to the dangers of the industry, but as this investigation proves, the battle for the integrity of Swiss science is only just beginning.